Rockwell Medical Reports Strong Q4 2025 Revenue Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 11 2026
0mins
Source: Yahoo Finance
Rockwell Medical Inc. shares surged by 24.10% as the stock reached a 20-day high amid broader market declines.
The company reported anticipated Q4 2025 net sales of approximately $18.6 million, exceeding analysts' expectations of $16.55 million, which indicates strong market performance. Additionally, the gross margin is expected to improve to 22%, up from 14% in Q3 2025, reflecting effective cost control measures. CEO Mark Strobeck emphasized a strategic focus on revenue growth and profitability for 2026.
This positive outlook and the exceeding sales forecast are likely to enhance investor confidence, positioning Rockwell Medical for potential long-term success despite the current market challenges.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RMTI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RMTI
Wall Street analysts forecast RMTI stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.651
Low
2.50
Averages
3.75
High
5.00
Current: 0.651
Low
2.50
Averages
3.75
High
5.00
About RMTI
Rockwell Medical, Inc. is a healthcare company. The Company develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers worldwide. The Company operates in the hemodialysis market, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceuticals, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. Its hemodialysis concentrates products are used to sustain a patient's life by removing toxins and balancing electrolytes in a dialysis patient’s bloodstream. The Company is the supplier of liquid and dry, acid and bicarbonate concentrates for dialysis patients in the United States. The Company manufactures hemodialysis concentrates at its facilities in Michigan, South Carolina, and Texas, and the Company manufactures its dry acid concentrate mixers at its facility in Iowa.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rockwell Medical Announces 1-for-10 Reverse Stock Split
- Reverse Stock Split: Rockwell Medical's Board has authorized a 1-for-10 reverse stock split to comply with Nasdaq's minimum bid price requirement of $1.00 per share, ensuring continued listing and enhancing liquidity and market visibility.
- Effective Date: The reverse stock split will take effect on July 1, 2026, automatically converting every 10 shares into 1 new share, while preserving shareholder rights and adjusting related equity awards and convertible preferred stock accordingly.
- Shareholder Rights Protection: The reverse stock split will not affect the number of authorized shares, and shareholders entitled to fractional shares will receive cash compensation, ensuring all shareholder interests are adequately addressed and maintaining the company's reputation.
- Agent Appointment: Equiniti Trust Company LLC has been appointed as the exchange agent for the reverse stock split, ensuring automatic adjustments for shareholders and simplifying their processes, thereby enhancing the company's professional image in the capital market.
See More
Rockwell Medical Announces Reverse Stock Split to Regain Nasdaq Compliance
- Reverse Stock Split Plan: Rockwell Medical has announced a 1-for-10 reverse stock split effective July 1, 2026, primarily aimed at regaining compliance with Nasdaq's minimum bid price requirement of $1 per share, thereby mitigating the risk of delisting.
- Compliance Deadline: Nasdaq has granted Rockwell a 180-day period until November 4, 2026, to regain compliance after the stock traded below the required minimum bid price of $1 for 30 consecutive business days, highlighting the urgency of the situation.
- Declining Financial Performance: In its first-quarter report, Rockwell Medical reported net sales of $17.3 million, an 8% decrease attributed to lower purchase volumes from a single customer, while net loss widened to $1.6 million, indicating significant financial challenges ahead.
- Market Sentiment: Despite a slight pre-market drop in RMTI shares, retail sentiment on Stocktwits remains in the 'extremely bullish' zone, reflecting investor confidence in the company's future, even as the stock has declined over 24% year-to-date.
See More
Rockwell Medical Approves 1-for-10 Reverse Stock Split
- Reverse Stock Split Decision: Rockwell Medical's board approved a 1-for-10 reverse stock split effective July 1, 2026, aimed at regaining compliance with Nasdaq, ensuring the company maintains its listing status and attracts institutional investors.
- Shareholder Authorization Context: The reverse split was authorized by shareholders at the annual meeting on June 12, indicating that the company is taking measures to address current market challenges with shareholder support.
- Market Reaction: Following the announcement of the reverse split, Rockwell Medical's shares fell approximately 6% during pre-market trading on Monday, reflecting market concerns about the company's future prospects, which could impact its liquidity and capital access.
- Future Outlook: Rockwell Medical projects net sales between $70 million and $75 million for 2026 while targeting positive net income in the second half of 2026, demonstrating the company's determination to seek growth amid adversity.
See More
Rockwell Medical Renews Agreement with aQua Dialysis
- Agreement Renewal: Rockwell Medical has renewed its two-year product purchase agreement with aQua Dialysis in Texas, with options for two additional one-year extensions, ensuring stable product supply and enhancing the company's competitive position in the market.
- Supply Commitment: Under the agreement, Rockwell Medical will continue to supply aQua Dialysis with liquid and dry acid and bicarbonate hemodialysis concentrates and other essential dialysis-related products, which not only solidifies their long-term partnership but also boosts customer trust in product quality.
- Strengthened Customer Relations: Tim Chole, Chief Commercial Officer of Rockwell Medical, stated that the renewal reflects the strong relationship with aQua Dialysis, indicating high customer recognition of the company's product quality and service, further enhancing brand value.
- Industry Impact: Rockwell Medical is committed to providing high-quality products and services for dialysis patients, and with its strong reputation and reliability in the industry, it is expected to attract more customers and partners, driving long-term growth for the company.
See More
Rockwell Medical Enters Three-Year Purchase Agreement with Heritage Dialysis
- Strategic Partnership: Rockwell Medical has signed a three-year product purchase agreement with Michigan-based Heritage Dialysis, covering a range of hemodialysis products including the 720g bicarbonate cartridge PureCart, aimed at meeting Heritage Dialysis's flexible needs across various environments, thereby enhancing competitive positioning for both parties.
- Product Portfolio Advantage: Under the agreement, Rockwell Medical will supply Heritage Dialysis with products such as liquid acetic acid-based RenalPure® and liquid bicarbonate SteriLyte®, which will support Heritage Dialysis's operations in home dialysis and skilled nursing facilities, improving patient treatment experiences.
- Long-Term Growth Potential: Ryan Height, Founder and CEO of Heritage Dialysis, stated that the collaboration will transform renal care by combining state-of-the-art technology with optimal treatment plans, which is expected to provide better health and wellness for patients, further solidifying Rockwell Medical's position in the industry.
- Industry Recognition: Rockwell Medical has been certified as a Great Place to Work® for four consecutive years and named Fortune's Best Workplaces in Manufacturing & Production™ for 2024 and 2025, demonstrating its commitment to delivering high-quality dialysis solutions and customer service, which enhances its market appeal.
See More
Rockwell Medical Q1 2026 Earnings Call Insights
- Profitability Outlook: CEO Mark Strobeck indicated that Rockwell Medical aims for positive net income in the second half of 2026, despite customary risks and uncertainties, marking a significant step towards sustainable profitability.
- Sales Performance Review: The first quarter net sales reached $17.3 million, exceeding expectations but declining year-over-year due to reduced volumes from the largest customers, highlighting the risk of customer concentration.
- Automation Investment: The company plans to activate two new automated liquid production lines this quarter, which are expected to increase output by approximately 50% and significantly reduce manufacturing costs per bottle, potentially generating an additional $3 million in gross profit in 2026.
- Annual Guidance Update: Management provided guidance for 2026, projecting net sales between $70 million and $75 million, gross margins of 18% to 22%, and adjusted EBITDA of $1 million to $2 million, indicating a path towards positive cash flow and profitability in the future.
See More
Rockwell Medical Announces 1-for-10 Reverse Stock Split
- Reverse Stock Split: Rockwell Medical's Board has authorized a 1-for-10 reverse stock split to comply with Nasdaq's minimum bid price requirement of $1.00 per share, ensuring continued listing and enhancing liquidity and market visibility.
- Effective Date: The reverse stock split will take effect on July 1, 2026, automatically converting every 10 shares into 1 new share, while preserving shareholder rights and adjusting related equity awards and convertible preferred stock accordingly.
- Shareholder Rights Protection: The reverse stock split will not affect the number of authorized shares, and shareholders entitled to fractional shares will receive cash compensation, ensuring all shareholder interests are adequately addressed and maintaining the company's reputation.
- Agent Appointment: Equiniti Trust Company LLC has been appointed as the exchange agent for the reverse stock split, ensuring automatic adjustments for shareholders and simplifying their processes, thereby enhancing the company's professional image in the capital market.
See More
Rockwell Medical Announces Reverse Stock Split to Regain Nasdaq Compliance
- Reverse Stock Split Plan: Rockwell Medical has announced a 1-for-10 reverse stock split effective July 1, 2026, primarily aimed at regaining compliance with Nasdaq's minimum bid price requirement of $1 per share, thereby mitigating the risk of delisting.
- Compliance Deadline: Nasdaq has granted Rockwell a 180-day period until November 4, 2026, to regain compliance after the stock traded below the required minimum bid price of $1 for 30 consecutive business days, highlighting the urgency of the situation.
- Declining Financial Performance: In its first-quarter report, Rockwell Medical reported net sales of $17.3 million, an 8% decrease attributed to lower purchase volumes from a single customer, while net loss widened to $1.6 million, indicating significant financial challenges ahead.
- Market Sentiment: Despite a slight pre-market drop in RMTI shares, retail sentiment on Stocktwits remains in the 'extremely bullish' zone, reflecting investor confidence in the company's future, even as the stock has declined over 24% year-to-date.
See More
Rockwell Medical Approves 1-for-10 Reverse Stock Split
- Reverse Stock Split Decision: Rockwell Medical's board approved a 1-for-10 reverse stock split effective July 1, 2026, aimed at regaining compliance with Nasdaq, ensuring the company maintains its listing status and attracts institutional investors.
- Shareholder Authorization Context: The reverse split was authorized by shareholders at the annual meeting on June 12, indicating that the company is taking measures to address current market challenges with shareholder support.
- Market Reaction: Following the announcement of the reverse split, Rockwell Medical's shares fell approximately 6% during pre-market trading on Monday, reflecting market concerns about the company's future prospects, which could impact its liquidity and capital access.
- Future Outlook: Rockwell Medical projects net sales between $70 million and $75 million for 2026 while targeting positive net income in the second half of 2026, demonstrating the company's determination to seek growth amid adversity.
See More
Rockwell Medical Renews Agreement with aQua Dialysis
- Agreement Renewal: Rockwell Medical has renewed its two-year product purchase agreement with aQua Dialysis in Texas, with options for two additional one-year extensions, ensuring stable product supply and enhancing the company's competitive position in the market.
- Supply Commitment: Under the agreement, Rockwell Medical will continue to supply aQua Dialysis with liquid and dry acid and bicarbonate hemodialysis concentrates and other essential dialysis-related products, which not only solidifies their long-term partnership but also boosts customer trust in product quality.
- Strengthened Customer Relations: Tim Chole, Chief Commercial Officer of Rockwell Medical, stated that the renewal reflects the strong relationship with aQua Dialysis, indicating high customer recognition of the company's product quality and service, further enhancing brand value.
- Industry Impact: Rockwell Medical is committed to providing high-quality products and services for dialysis patients, and with its strong reputation and reliability in the industry, it is expected to attract more customers and partners, driving long-term growth for the company.
See More
Rockwell Medical Enters Three-Year Purchase Agreement with Heritage Dialysis
- Strategic Partnership: Rockwell Medical has signed a three-year product purchase agreement with Michigan-based Heritage Dialysis, covering a range of hemodialysis products including the 720g bicarbonate cartridge PureCart, aimed at meeting Heritage Dialysis's flexible needs across various environments, thereby enhancing competitive positioning for both parties.
- Product Portfolio Advantage: Under the agreement, Rockwell Medical will supply Heritage Dialysis with products such as liquid acetic acid-based RenalPure® and liquid bicarbonate SteriLyte®, which will support Heritage Dialysis's operations in home dialysis and skilled nursing facilities, improving patient treatment experiences.
- Long-Term Growth Potential: Ryan Height, Founder and CEO of Heritage Dialysis, stated that the collaboration will transform renal care by combining state-of-the-art technology with optimal treatment plans, which is expected to provide better health and wellness for patients, further solidifying Rockwell Medical's position in the industry.
- Industry Recognition: Rockwell Medical has been certified as a Great Place to Work® for four consecutive years and named Fortune's Best Workplaces in Manufacturing & Production™ for 2024 and 2025, demonstrating its commitment to delivering high-quality dialysis solutions and customer service, which enhances its market appeal.
See More
Rockwell Medical Q1 2026 Earnings Call Insights
- Profitability Outlook: CEO Mark Strobeck indicated that Rockwell Medical aims for positive net income in the second half of 2026, despite customary risks and uncertainties, marking a significant step towards sustainable profitability.
- Sales Performance Review: The first quarter net sales reached $17.3 million, exceeding expectations but declining year-over-year due to reduced volumes from the largest customers, highlighting the risk of customer concentration.
- Automation Investment: The company plans to activate two new automated liquid production lines this quarter, which are expected to increase output by approximately 50% and significantly reduce manufacturing costs per bottle, potentially generating an additional $3 million in gross profit in 2026.
- Annual Guidance Update: Management provided guidance for 2026, projecting net sales between $70 million and $75 million, gross margins of 18% to 22%, and adjusted EBITDA of $1 million to $2 million, indicating a path towards positive cash flow and profitability in the future.
See More
